ClinicalTrials.gg
CompletedNCT04769388FLAMEUpdated Nov 6, 2026

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

A Phase 2 interventional study of Osimertinib and Pemetrexed/Carboplatin in Non Small Cell Lung Cancer, sponsored by Beijing Cancer Prevention & Treatment Society. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Beijing Cancer Prevention & Treatment Society · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Nov 6, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
104th of 224
80 · median 65
Started
2022
with 8 others
Phase 2
128 of 228
12 open now
Registered
201st of 228
by date

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 104th largest by enrollment of the 224 interventional ones that give a count, is one of 9 that started in 2022, is one of 128 in phase 2, and was the 201st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a prospective, randomised, open-label, positive-controlled study to investigate the efficacy and safety of Osimertinib plus Carboplatin/Pemetrexed versus Osimertinib monotherapy in locally advanced or metastatic EGFRm NSCLC patients with EGFRm persistence in ctDNA at 3 weeks after first-line therapy with Osimertinib.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision and signed of prior to any study specific procedures;
  • Male or female, aged at least 18 years;
  • (ECOG) performance-status score of 0 or 1;
  • Newly diagnosed, and documented locally advanced or non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology ), and classified as stage IIIB, IIIC, IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy;
  • of at least 3 months at recruitment;
  • Only the patients receiving osimertinib as 1L treatment and meeting the following criteria will be considered:

A. Prior to 1L osimertinib:

  1. History of EGFRm (exon 19 deletion or exon 21 L858R) in the plasma ctDNA by the local testing methods.
  2. No previous systemic treatment. therapies, or definitive radiation/chemoradiation are permitted as long as treatment was completed at least 6 months prior to receiving 1L treatment.
  3. Patients with asymptomatic and stable for at least 2 weeks will be allowed, including .

B. Prior to randomization: Patients after 3 weeks of 1L osimertinib treatment who have persistence ctDNA EGFRm by SuperARMS at 3 weeks will be considered to be enrolled. They will need to further meet the criteria below before randomization:

  1. Patients without disease progression by 1.1 evaluation;
  2. At least 1 measurable extracranial lesion according to RECIST 1.1 .
  3. Female subjects should be using highly effective measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of , or must have evidence of non-child-bearing potential.
  4. Male subjects should be willing to agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study;
  • History of to active or inactive of Osimertinib and/or Pemetrexed and/or Carboplatin or drugs with a similar chemical structure or class to Osimertinib and/or Pemetrexed and/or Carboplatin;
  • For patients, inability to collect plasma samples at baseline and disease progression;
  • or any abnormalities in rhythm;
  • Any evidence of severe or uncontrolled systemic diseases;
  • Currently receiving medications or herbal supplements known to be strong inducers of ;
  • Any unresolved toxicities from prior therapy greater than 5.0 grade 1 at the time of starting study treatment.
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  • Inadequate bone marrow reserve or organ function;
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  • for osimertinib, pemetrexed and carboplatin according to China approved label.
  • Women who are pregnant or breast-feeding.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Osimertinib 80 mg QD and platinum-based chemotherapy

    Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

    Drug: Osimertinib · Drug: Pemetrexed/Carboplatin

  • Active comparator
    Osimertinib 80mg QD

    All patients randomized into this will only receive Osimertinib 80mg.

    Drug: Osimertinib

Interventions

  • Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

    Also known as: AZD9291, Tagrisso

  • DrugPemetrexed/Carboplatin

    Drug pages: PemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

    Time frame: The analysis of PFS based on Investigator assessment (according to RECIST 1.1) will occur when approximately 54 progression events have been observed in the 80 randomized patients (approximately 67.5% PFS maturity).

Secondary outcomes

  1. OS rate at 18 months

    Proportion of patients alive at 18 months

    Time frame: The OS rate at 18 months will be defined as the Kaplan-Meier estimate of OS at 18 months.

  2. Objective Response Rate (ORR)

    ORR (per RECIST 1.1 using Investigator assessments) is defined as the number (percent) of patients with at least 1 visit response of CR or PR.

    Time frame: Objective Response Rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.

  3. Disease Control Rate (DCR)

    Disease control rate (DCR) is defined as the percentage of subjects who have a best overall response of CR or PR or SD by RECIST 1.1 as assessed by the Investigator.

    Time frame: Disease control rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.

  4. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression.

    Time frame: Duration of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.

  5. Depth of Response

    Depth of response by Investigator is defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of NLs or progression of NTLs when compared to baseline.

    Time frame: Depth of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.

  6. Safety and tolerability: Adverse event

    All Adverse events/≥grade 3 AE/SAE incidence rate (AE/SAE graded by CTCAE v5); All ADR incidence rate; AESI: ILD/pneumonitis-like event, Cardiac failure

    Time frame: Safety and tolerability analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.

  7. Molecular resistance mechanism

    To evaluate potential molecular resistance mechanism by biomarker analysis of plasma at baseline and disease progression and tissue samples (if applicable) by next-generation sequencing (NGS).

    Time frame: Molecular resistance mechanism analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.

07

Study locations

1 site
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jan 2026, 47 months.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 47 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Dec 2021 → Feb 2022, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2021
First posted
Feb 24, 2021
StartActual
Feb 7, 2022was Dec 2021
Primary completionActual
Jan 26, 2026
CompletionActual
Jan 26, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 28, 2021→Feb 7, 2022
Nov 6, 2026
Primary completion
Jan 24, 2026→Jan 26, 2026
Nov 6, 2026
Study completion
Jan 24, 2026→Jan 26, 2026
Nov 6, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedNewly diagnosed, and histologically documented locally advanced or metastatic non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology ), and classified as stage IIIB, IIIC, IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy;
Nov 2, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameProgression free survivalThe primary analysis of Progression-free survival (PFS) based on investigator assessment will occur when PFS maturity is observed at approximately 30 months after the first patient is randomized. → The analysis of PFS based on Investigator assessment (according to RECIST 1.1) will occur when approximately 54 progression events have been observed in the 80 randomized patients (approximately 67.5% PFS maturity).
Nov 2, 2026
Secondary outcomes
6 time frame changed
What changed in the outcomes
  • Time frameObjective Response Rate (ORR)Objective Response Rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Objective Response Rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
  • Time frameDisease Control Rate (DCR)Disease control rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Disease control rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
  • Time frameDuration of Response (DoR)Duration of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Duration of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
  • Time frameDepth of ResponseDepth of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Depth of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
  • Time frameSafety and tolerability: Adverse eventSafety and tolerability analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Safety and tolerability analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
  • Time frameMolecular resistance mechanismMolecular resistance mechanism analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Molecular resistance mechanism analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Start date Dec 28, 2021→Feb 7, 2022
    Primary completion Jan 24, 2026→Jan 26, 2026
    Study completion Jan 24, 2026→Jan 26, 2026
    Secondary outcomes 6 time frame changed
    What changed in the outcomes
    • Time frameObjective Response Rate (ORR)Objective Response Rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Objective Response Rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
    • Time frameDisease Control Rate (DCR)Disease control rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Disease control rate analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
    • Time frameDuration of Response (DoR)Duration of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Duration of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
    • Time frameDepth of ResponseDepth of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Depth of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
    • Time frameSafety and tolerability: Adverse eventSafety and tolerability analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Safety and tolerability analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
    • Time frameMolecular resistance mechanismMolecular resistance mechanism analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 30 months from the first patient being randomized. → Molecular resistance mechanism analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 31 months from the first patient being randomized.
    + 1 other change: verification date
  2. Nov 2, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedNewly diagnosed, and histologically documented locally advanced or metastatic non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology ), and classified as stage IIIB, IIIC, IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy;
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameProgression free survivalThe primary analysis of Progression-free survival (PFS) based on investigator assessment will occur when PFS maturity is observed at approximately 30 months after the first patient is randomized. → The analysis of PFS based on Investigator assessment (according to RECIST 1.1) will occur when approximately 54 progression events have been observed in the 80 randomized patients (approximately 67.5% PFS maturity).
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04769388
Lead sponsor
Beijing Cancer Prevention & Treatment Society
Responsible party
Sponsor
First posted
Feb 24, 2021
Start date
Feb 7, 2022
Primary completion
Jan 26, 2026
Completion
Jan 26, 2026
Last update
Nov 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Carboplatin

Start the discussion